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Abbreviations: 
AR: acute rejection 
BAL: bronchoalveolair lavage 
BOS: bronchiolitis obliterans syndrome 
CAV-1: caveolin-1 
CD14: cluster of differentiation 14 
CF: cystic fibrosis 
CI: confidence interval 
CMV: cytomegalovirus,  
COPD: chronic obstructive pulmonary disease 
CRP: C-reactive protein 
GERD: gastroesophageal reflux disease 
HL: heart-lung transplantation 
HR: hazard ratio 
IFN-γ: interferon gamma 
IL-17RA: Interleukin-17 receptor A 
IL-23R: Interleukin-23 receptor 
KIRs: killer immunoglobulin-like receptors 
LB: lymphocytic bronchiolitis 
LTx: lung transplantation 
MMP-7: matrix metalloproteinase-7 
PGD: primary graft dysfunction. 
SLTx: single lung transplantation 
SSLTx: bilateral lung transplantation 
TGF-β1: transforming growth factor beta-1 
TLR: toll like receptors 
TNF-α: tumor necrosis factor alfa 
WBC: white blood cells 
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ABSTRACT 
Chronic rejection is the major cause of morbidity and mortality after lung transplantation. IL-
17 producing cells, inducers of airway neutrophilia, play a prominent role in chronic rejection.  
We investigated the association between genetic variants in the IL-17/IL-23 pathway and 
outcome after lung transplantation. Six genetic variants in IL-17 and IL-23 receptor genes 
were genotyped in 497 lung transplant patients. Associations with chronic rejection, mortality, 
airway and systemic inflammatory parameters were assessed.  The rs879574A, genetic variant 
in the IL-17A receptor gene, was associated with chronic rejection. In particular, carriers of 
the rs879574 at-risk A-allele exhibited increased susceptibility to chronic rejection with 
multivariable-adjusted hazard ratio of 1.47 (CI=1.07-2.03; p=0.004), but no association was 
found with mortality (CI=0.71-1.41; p=0.14). Also the prevalence of acute rejection was 
higher in the at-risk population (p=0.001). Interestingly, rs879574A was associated with 
airway neutrophilia (p=0.020), suggesting that this variant may functionally affect the IL-17A 
receptor gene and thereby contribute to chronic rejection after lung transplantation.  We 
conclude that rs879574A is associated with chronic rejection after lung transplantation, and is 
functionally associated with airway neutrophilia. Pre-transplant determination of this genetic 
variant may improve treatment and follow-up of our patients, aiming to reduce acute and 
chronic rejection.  
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INTRODUCTION 
Lung transplantation (LTx) is the ultimate treatment option for selected patients suffering 
from specific end-stage pulmonary disorders. However, after LTx, mortality rates remain 
relatively high, mainly due to the occurrence of chronic rejection (1). Chronic rejection, also 
defined as bronchiolitis obliterans syndrome (BOS) and characterized by an irreversible 
obstructive lung function, threatens over 50% of the lung transplant recipients within 5 years 
after LTx (2). Chronic rejection is accepted to be both an alloantigen dependent and 
independent process for which many risk factors have been identified, including acute 
rejection, lymphocytic bronchiolitis, the presence of auto-antibodies against collagen V, 
colonization with micro-organisms and air pollution (3-5). These insults will activate the 
immune system and increase airway neutrophilia, which will lead to epithelial damage, 
excessive airway wall repair and finally fibrosis/obliteration of the airways (1;6). However, 
the underlying mechanisms of chronic rejection remain to be elucidated. It is suggested that 
IL-17 producing T-cells are key cells to induce a severe neutrophilic response linked to 
several chronic inflammatory conditions, including COPD, asthma and cystic fibrosis (7;8). 
The prominent role of IL-17 T-cells is confirmed in lung biopsies of patients suffering from 
these severe respiratory diseases (9-12). After LTx, IL-17 is involved in ischemic reperfusion 
injury (13), but also in acute (14) and chronic rejection (15).  
Genetic predisposition may also play a role in chronic rejection after LTx. But, its role 
has not yet been thoroughly investigated, mainly due to smaller cohort sizes. Single center 
studies were unsuccessful to associate genetic variants in the genes encoding tumor necrosis 
factor alfa (TNF-α), interleukins (IL-6, IL-10), interferon gamma (IFN-γ) and transforming 
growth factor beta-1 (TGF-β1) with the development of chronic rejection (16-20). On the 
other hand, some small cohort studies could associate chronic rejection with genetic variants 
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in toll like receptors (TLR-2, TLR-4, TLR-9), CD14, caveolin-1 (CAV-1), killer 
immunoglobulin-like receptors (KIRs), and matrix metalloproteinase-7 (MMP-7) (19;21-27). 
In the present study, we postulate that genetic variants in IL-17 receptor (IL-17R) and 
IL-23 receptor (IL-23R) genes may predispose lung transplant patients to increased risk for 
chronic rejection and possibly death. Therefore, we aimed to investigate the association 
between genetic variants in IL-17R and IL-23R genes with outcome after LTx in the Leuven 
Lung Transplant cohort. In particular, our specific aims were: i) to investigate the association 
between IL-17R and IL-23R genetic variants, chronic rejection and mortality after LTx and ii) 
to assess the correlation between the selected variants and airway neutrophilia. 
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METHODS 
Study design 
This study included the entire Leuven lung transplant cohort that was recruited 
between April 1991 and December 2010. Patient‟s follow-up was recorded until August  
2011, resulting in a minimal follow-up of at least 7 months. The study was approved by the 
Ethics Committee (S54739) of the Leuven University Hospitals, and all subjects consented 
prior to study participation. All patients received triple immunosuppression with cyclosporine 
or tacrolimus, azathioprine or mycophenolate mophetil, corticosteroids and an induction 
treatment of rabbit anti-thymocyte globulin (rATG). Chronic rejection was defined according 
to International Society for Heart and Lung Transplantation (ISHLT) criteria (2). Chronic 
rejection is defined as a persistent decline of FEV1 of at least 20% compared to the best post-
operative value where no other explanation was found using CAT scan, bronchoscopy,   
transbronchial biopsies, bronchoalveolar lavage and cultures. Acute rejection (AR) and 
lymphocytic bronchiolitis (LB) were defined on histopathology according to the ISHLT 
guidelines (28). AR/LB was analyzed as a binary variable by contrasting at least one AR/LB 
event during follow-up versus being free of AR or LB. Also “severe” grades of AR (≥A2)/LB 
(>B2, according to the old histopathological criteria for LB) were analyzed separately. Acute 
rejection was treated with a 3 day course of high dose intravenous corticosteroids with 
subsequent oral tapering or an increased oral steroid boost. Chronic rejection was treated with 
an increase or shift in immunosuppression or oral tempered dose of steroids, azitromycin, 
total lymphoid irradiation and/or montelukast (29).  
Patient‟s characteristics included gender, age, time of LTx, type of LTx (single lung 
transplantation (SLTx) versus bilateral lung transplantation (SSLTx) and heart-lung 
transplantation (HL)) and type of underlying lung disease. Clinical follow-up data included 
ischemic time, primary graft dysfunction (PGD) at 48 hours after LTx (30), the number of 
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acute rejections, lymphocytic bronchiolitis, respiratory infections, CMV infections (29), CMV 
status (donor/recipient), gastroesophageal reflux disease (GERD, assessed either by pH 
impedance or gastroscopy within the first 2 years after transplantation) (29),  bronchoalveolar 
lavage (BAL) cell profile, C-reactive protein (CRP, which is a marker for systemic 
inflammation), date of diagnosis of chronic rejection, start of azithromycin therapy and day of 
death. Infections were defined as respiratory events with need for antibiotics or 
hospitalization. Bronchoscopies with BAL (2x50ml of saline) and biopsy in combination with 
cell count/differentiation and histological evaluation were performed routinely at defined 
intervals (90, 180, 360 days) post-transplantation, as previously reported (31). The systemic 
collection of BAL in our centre was started in 2001. We included all patients for whom a 
BAL was available on at least one of the following postoperative days 90, 180, and 360. The 
number of subjects in all analysis is reported in Table 1: at day 90 (n=250 TT, n=80 AA+AT), 
day 180 (n=228 TT, n=75 AA+AT) and at day 360 (n=222 TT, n=69 AA+AT). In total 266 
patients of the TT-genotype (71%) and 85 patients of the AA/AT genotype (69%) had at least 
one BAL at the different time points. CxCL8 (IL-8)  in BAL fluid was determined by ELISA, 
as previously described (4).  Retransplantation (n=23) was considered as a separate 
transplantation for outcome analyses, since a second allograft was evaluated in an already 
genotyped recipient, as previously described (5). 
 
Genotyping 
Recipient DNA was extracted from peripheral blood or, when unavailable, from explanted 
lung tissue. DNA from blood samples was extracted using the Qiagen QIAamp DNA Blood 
Midi kit according to the supplier‟s instructions (Qiagen, Hilden, Germany). For DNA 
extraction from lung tissue embedded in paraffin blocks, paraffin was removed by xylene, 
followed by two washes with ethanol. After the paraffin removal steps, tissue was digested 
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with proteinase K solution and DNA was extracted by using Qiagen DNeasy Blood & Tissue 
kit (according to the supplier‟s instructions). For the control of DNA purity, 1 μl of genomic 
DNA was used to measure the 260/280 and 260/230 ratios by use of a Nanodrop-1000 
(NanoDrop Technologies,Wilmington, DE). Only samples with a 260/280 ratio <2 and a 
260/230 ratio <1 were accepted. DNA (5ng/µl) was aliquoted into 384-well plates and 
genotyped at the Vesalius Research Center (Leuven).  
Genotyping for rs879574 (IL-17RA gene), rs2201841 (IL-23R gene), rs10489628 (IL-
23R gene), rs2066808 (IL-23A gene), rs1343151 (IL-23R gene) and rs1569922 (IL-23R gene) 
(32-37) was performed in a blinded manner using iPLEX technology on a MassARRAY 
Compact Analyser (Sequenom Inc., San Diego, CA, USA), as reported previously (38;39) . 
Automated genotyping calls were generated using the MassARRAY RTTM software and 
were validated by manual review of the raw mass spectra. Quality control was performed by 
genotyping 12 samples in duplicate, with a duplicate concordance of 100%.  
 
Statistical analysis 
Graph prism 4.0 software (San Diego, CA, USA) was used for statistical analysis of patient 
characteristics. Results are presented in numbers (percentage) or with the mean ± SEM. 
Mann-Whitney test (non-parametric t-test), chi-square (contingency tables) and one-way 
ANOVA (Kruskal-Wallis) where used, where appropriate. A p-value < 0.05 was considered 
significant. 
For further database management and statistical analysis, we used SAS software, version 9.2 
(SAS Institute Inc, Cary, NC). We performed survival analysis to study the effect of genotype 
on the hazard of chronic rejection (primary analysis). Patients for whom the endpoint was not 
observed before 1/8/2011 were treated as censored observations. In the analysis of chronic 
rejection, observations were also censored, when the patient died without evidence of chronic 
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rejection. For each patient, the exact date of the endpoint or censoring was available. The 
survival analysis was performed for 6 genes. Therefore, we used the Bonferroni correction 
method in this analysis, which resulted in a significance threshold of p<0.0083. The p-values 
reported in the text are unadjusted. In our study, secondary analysis on the effect of genotypes 
on the hazard of mortality was performed. We contrasted survival curves by Kaplan-Meier 
survival function estimates and the log-rank test. We applied Cox regression to estimate the 
hazard ratio of chronic rejection and mortality associated with the genotypes for the selected 
genetic variants, while adjusting for age, gender, time of LTx, type of LTx, underlying lung 
disease and use of azithromycin. All these variables were a priori chosen.  
A mixed model allowing for subject-specific intercepts and slopes was used to investigate the 
effect of the rs879574 genotypes (AA/AT versus TT) on i) the total number and percentage 
neutrophilia in BAL fluid, ii) the total number and percentage of white blood cells (WBC) in 
BAL fluid, iii) concentration of CxCL8 (IL-8) in BAL fluid, and iv) serum CRP measured 90, 
180, and 360 days after transplantation. All dependent variables were transformed 
logarithmically to normalize the distribution of the residuals. The covariates age, gender, time 
of LTx, type of LTx, type of underlying lung disease, and use of azithromycin were included 
in the model. 
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RESULTS 
Study population  
In total, we included 568 patients. For 43 patients, DNA extraction failed and, consequently, 
no DNA was available for genotyping.  The genotyping success rate for each of the 6 selected 
variants in the remaining 525 patients was higher than 90% (90% to 96%).  
 First, we assessed whether any of the selected genetic variants associated with our 
primary endpoint, i.e. chronic rejection. We could not find an association for any of the 
genetic variants in IL-23R genes. On the other hand, the IL-17RA genetic variant 
(rs879574A) did influence chronic rejection after LTx. The genotyping success rate for 
rs879574 was 95%.  
 
The rs879574A population characteristics 
Of the 497 successfully genotyped patients, 373 carried the TT genotype, 113 the AT 
genotype and 11 the AA genotype. Patient‟s characteristics according to AA/AT and TT 
genotypes are summarized in Table 1. There were no significant differences in gender 
(p=0.84), age (p=0.91), era of LTx (before 2001 versus after 2001) (p=0.99), type of LTx 
(p=0.58) and type of underlying lung disease (p=0.15) between both subgroups. 
Immunosuppressive treatment did not differ between the genotypes comparing azathioprine 
versus mycophenolate mophetil (p=0.85) and tacrolimus versus cyclosporine (p=0.69). 
Race/ethnicity between the both genotypes did not differ (p=0.18) in our predominantly 
Caucasian population (in the AA/AT and TT genotype respectively 96% and 98%). 
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The rs879574A variant correlates with chronic rejection after LTx 
As mentioned above, we identified a significant association between rs879574A and chronic 
rejection. In particular, the rs879574 A-allele was significantly more common in patients 
diagnosed with chronic rejection (18% versus 11%, respectively in the group with and 
without chronic rejection, p=0.002), suggesting that the A-allele is the at-risk allele for 
rs879574. These findings are consistent with a recent paper identifying an increased risk of 
Crohn‟s disease in patients carrying the rs879574 A-allele (37). The frequency of the A-allele 
was 14% in our study population, which is comparable to the frequency in the general 
European population (40).  
At the genotypic level, the estimated risk of subjects carrying one risk allele (A-allele) 
was significantly higher than the risk of those carrying no A-allele, but was comparable to the 
risk of homozygous A-allele carriers (hazard ratio (HR) of 1.63 and 1.86, respectively for the 
AA and AT genotype). These results indicate a dominant effect of the risk allele and, 
therefore, we analyzed the association of rs879574A with outcome after LTx using a 
dominant model (i.e. AA/AT versus the TT genotype). In univariate analysis, rs879574A 
significantly associated with an increased risk of chronic rejection (p=0.0034 according to a 
dominant risk model, figure1A).  When adjusting for age, gender, date of transplantation, LTx 
type, diagnosis and use of azithromycin, we identified an almost 50% higher risk of chronic 
rejection for the AA/AT genotype compared to the TT genotype (HR=1.47, 95% CI: [1.07-
2.03], p=0.004) (Table 2). Multi-variate analysis excluding retransplantations (n=23, TT 
genotype n=17 and AT/TT genotype n=6) showed comparable results.  
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The rs879574A variant does not correlate with mortality after LTx 
Unadjusted no significant difference was identified in mortality rates between 
rs879574 genotypes (p=0.24, figure 1B). The mortality curves were similar the first 3 years 
after transplantation, but seemed to diverge in favor of carriers of the TT-genotype afterwards. 
Our exploratory (unadjusted) analysis excluding the first three years after transplantation 
suggested a higher mortality in the AT/TT-subgroup (p=0.049) (figure 1C).  The adjusted 
model confirmed the comparable mortality rates between rs879574 genotypes (p=0.16, table 
2) 
In the overall cohort, there was no significant relationship between the use of 
azithromycin and the development of chronic rejection (p=0.18), or the posttransplant 
survival (p=0.30). An important observation was that a higher proportion of patients were 
using azithromycin therapy in the AA+AT group compared to the TT group (p=0.047; Table 
1).  
 
 
Associations between rs879574A and risk factors  
 Acute rejection, one of the most important risk factors for chronic rejection, was more 
frequently observed after adjustment for confounders in the AA/AT-subgroup (p=0.001). On 
the other hand, we did not observe a significant difference between rs879574 genotypes and 
the presence of GERD (p=0.66), lymphocytic bronchiolitis (LB) (p=0.38), respiratory 
(bacterial and fungal) infections (p=0.20) and CMV infection (p=0.41) (table 1). In addition, 
there was also no difference in acute rejection grades (A≥2) (p=0.40), or LB (B>2) (p=0.17). 
Pretransplant donor-receptor status of CMV (p=0.81), ischemic time (p=0.42) and grade of 
primary graft dysfunction (p=0.61) did not differ between the genotypes. 
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The rs879574A variant correlates with BAL neutrophilia.   
 To confirm the potential functional relevance of rs879575A for LTx outcome, we 
assessed the association with BAL neutrophilia, BAL CxCL8 levels and serum CRP 
(measured at 90, 180, and 360 days after transplantation), while adjusting for age, gender, 
type of LTx, type of underlying disease, time of LTx and the use of azitromycin (Figure 2). In 
the AA/AT subgroup, percentage BAL neutrophilia was 1.59 times higher compared with the 
group of TT carriers (CI: [1.07-2.36], p=0.023). Likewise, total neutrophilia was 1.68 times 
higher for AA/AT subgroup than in the TT group (CI: [1.09-2.61], p=0.020). The effect on 
absolute number of BAL lymphocytes did not reach prespecified p-value (estimate: 1.30, CI: 
[0.97-1.74], p=0.082). Percentage of BAL lymphocytes did not differ significantly between 
both subgroups. Total white blood cell count in the BAL was 1.34 times higher in carriers of 
the AA and AT genotype (CI: [1.08-1.65], p=0.007). CxCL8 levels in BAL were comparable 
between both subgroups (estimate: 1.13, CI: [0.78-1.62], p=0.52). The systemic inflammation 
was evaluated by analyzing plasma CRP and tended to be higher in AA and AT carriers 
(estimate: 1.31, CI: [0.98-1.75], p=0.072) (tabel2).  
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DISCUSSION 
Our study is the first to identify a role of a genetic variant (rs879574) in the IL-17RA gene in 
chronic rejection after LTx (located in the IL-17RA of chromosome 22). Patients carrying the 
at-risk A-allele had a 47% increased risk of developing chronic rejection in comparison with 
carriers of the TT genotype (p=0.004). The A-allele also increased the risk of ever 
experiencing acute rejection (p=0.001), but did not influence the presence of lymphocytic 
bronchiolitis or respiratory infections after LTx (p=0.38 and p=0.22, respectively). 
Interestingly, rs879574 was associated with total airway neutrophilia (p=0.020), suggesting 
that this variant may functionally affect the IL-17RA gene and thereby contribute to chronic 
rejection after LTx.  
Recently, IL-17 producing T-cells have been associated with chronic rejection, as a 
driving factor of (airway) neutrophilia. Besides environmental and autoimmune 
differentiation/activation, we now demonstrated a genetic predisposition to chronic rejection 
via genetic variation in the IL-17RA gene. The IL-17 receptor is present on most cells within 
the lung, including immune cells and structural cells, and is specifically activated by IL-17, 
which may lead to an increased (airway) neutrophilia, via CxCL8 and other interleukin 
release (41). 
We believe that our findings are further strengthened by the demonstration of a 
functional consequence of the investigated IL-17RA genetic variant, as there is a link with 
increased airway neutrophilia at day 90, 180 and 360 after LTx, thus at time points preceding 
the diagnosis of chronic rejection. These findings are important, as persistent BAL 
neutrophilia is an established risk factor for chronic rejection (42). Total leukocyte count was 
associated with this genetic variant and trends were present for BAL lymphocytosis as well as 
serum CRP, which all are known to be involved in the development of chronic rejection. 
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Unfortunately, we were not able to demonstrate a link between rs879574A and 
CxCL8. This may be due to the large variation in measurements and larger range in BAL 
concentrations. Moreover, there are many more inducers of neutrophilia than CxCL8. Since 
acute rejection remains the most important risk factor for chronic rejection and it may be 
accompanied by increased IL-17 and neutrophilia in BAL samples (26), it is not surprising 
that the AA+AT group demonstrates more acute rejections. 
For the present study, we included 497 patients, making this one of the largest cohorts 
used for a genetic study in the field of LTx.  The single center approach may result in a more 
standardized and uniform care, which reduces possible bias by therapy. We are well aware 
that the lack of a replication cohort is a major concern, but finding a similar cohort of this size 
and with matched patient data was unfortunately not possible. On the other hand, we did 
demonstrate that this genetic variant in the IL-17RA gene had a functional effect on an 
accepted mechanistical element of chronic rejection after lung transplantation, being airway 
neutrophilia. However IL-17 protein levels in BAL is largely impossible to measure, based on 
previous experimental work done in our lab (41) . Therefore, we determined BAL 
neutrophilia and chronic rejection as a surrogate marker for IL-17, although we are aware that 
IL-17 is not the only inducer of BAL neutrophilia.    
Unexpectedly, we could not demonstrate a link between rs879574A and mortality after 
LTx. A possible explanation might be the use of azithromycin therapy, which is an accepted 
and effective treatment for chronic rejection and airway neutrophilia. Within our cohort, most 
of the patients (70%) only received azithromycin after diagnosis of chronic rejection (BOS), 
whereas only a small fraction (±10%) received it in a preventive manner. Previous studies 
demonstrated that overall mortality is reduced when receiving azithromycin (29). This may 
help to explain why we did not observe an association between rs879459A and crude 
mortality. Nevertheless, the link between the genetic variant in the IL17RA gene and airway 
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neutrophilia is reflected by a higher use of azithromycin in the subgroup carrying the AA or 
AT genotype (p=0.047) based on clinical indications. Therefore, azithromycin therapy was 
considered as a confounding factor in all analyses, however, an effect on the development of 
BOS (p=0.14) and mortality (p=0.30) could not be demonstrated. Hence, azithromycin does 
probably play a role in the association between the IL-17RA genetic variant and chronic 
rejection, but due to its widespread but unstandardized use during the last decade, we could 
not find a statistical difference. We are well aware that azithromycin usage is a poor endpoint 
to a genetic risk, although it can give an idea over the functionality of our polymorphism. The 
lack of an association between rs879574A and crude mortality could also be explained by the 
fact that chronic rejection needs time to develop and may only influence survival several 
years after diagnosis (43). This may explain the curve divergence after 3 years. Censoring for 
the first 3 years after LTx indeed showed a better survival in favor of the carriers of the TT-
genotype.  
Our findings are unique in the lung transplant field and need to be confirmed, but, if 
valid, may open several perspectives. They can be relevant for other chronic inflammatory 
pulmonary diseases such as COPD, CF and asthma, which are also IL-17/neutrophil related, 
and possibly also for other types of solid organ transplantation (8-11). In the clinical practice 
in our center, a systematic follow-up program with BAL is performed. When high BAL 
neutrophilia is detected, azithromycin is started as initial treatment when there is no indication 
for an infection. On the other hand, in some centers where no routine follow-up BAL is 
available, it can be useful to determine rs879547A prior to LTx to stimulate follow-up, given 
the known link between airway neutrophilia and chronic rejection. As mentioned before, 
untreated neutrophilia may indeed lead to chronic rejection (42). Early azithromycin treatment 
of patients with the at-risk A-allele for 879459 could therefore have an impact on the 
prevalence of chronic rejection. 
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In conclusion, we demonstrated that a genetic variant in the IL-17RA gene is 
associated with increased airway neutrophilia and the development of acute and chronic 
rejection. Determination of this genetic variant prior to LTx may change our point of view in 
the treatment and standard care follow-up of our patients by giving the „risk‟ group 
azithromycin early on to prevent the development of chronic rejection.  This, however, needs 
further prospective investigation.  
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FIGURE LEGENDS 
Figure 1: Freedom from chronic rejection (A) and mortality (B/C) according to rs879574 
genotypes (AA/AT versus TT). A) Unadjusted Kaplan-Meier curves in patients after LTx classified 
according to genotype: TT (n=124) versus AT and AA (n=373). AA+AT genotype has a significant 
higher risk for the development of chronic rejection (p=0.003)  
B) Unadjusted Kaplan-Meier survival curves in patients after LTx classified according to genotype: 
TT (n=124) versus AT and AA (n=373). AA+AT genotype has no significant higher risk for mortality 
(p=0.24)  
C) Unadjusted Kaplan-Meier survival curves in patients censored for the first 3 years after LTx 
classified according to genotype: AA+AT genotype implicates significant higher risk for mortality 
(p=0.049). With our current treatment for chronic rejection or BOS we only see an effect a few 
years after LTx. So this graph is shown, to see the long term effect of chronic rejection on 
mortality of this polymorphism.  
 
Figure 2: Association between the IL-17R polymorphism and different blood or BAL cellular 
characteristics. The effects are expressed as a multiplicative change of blood or cellular 
characteristics associated with the A-allele (AA and AT) compared with TT-genotype. The dotted 
line indicates no change in concentration or percentage. Red parameter estimates demonstrate 
a significant association, black a non-significant association. BAL= broncho-alveolair lavage, 
WBC= white blood cell count, CRP= C-reactive protein. 
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IL-17R polymorphism AA/ AT TT P-value 
Number of patients                124           373  
Female sex               57(46%) 177(47%) 0.84 
Age at LTx (years)    47.5(±1.2)  47.6(±0.6) 0.91 
Indication for LTx (n)   0.15 
            Emphysema,α-1ATD 49(40%) 179(48%) 0.16 
            Pulmonary fibrosis  25(20%)           51(14%) 0.09 
            CF/Bronchiectasis 19(15%)           64(17%) 0.64 
            Eisenmenger/PAHT 13(11%)           44(11%) 0.69 
            Retransplant/Others 18(14%)           35(10%) 0.11 
Transplantion time (transplanted after 
2001) 
95(77%)  286(77%) 0.99 
Type LTx(SS/HL compared with S) 91(73%)  283(76%) 0.58 
AZI treatment 65(53%)  156(42%)   0.04* 
Treatment 
Azathioprine-mycophenolatemophetil   
tacrolimus-cyclosporine   
                          
       80(65%) - 20(16%) 
       83(67%) - 32(26%) 
                           
  252(68%) - 51(14%) 
  241(65%) -105(28%) 
 
0.85 
0.69 
Acute rejection  history    
Any acute rejection (AR) 
Severe AR(≥A2) 
71(57%) 
23(18%) 
 146(39%) 
           63(17%) 
    0.001* 
0.40  
    Any lymphocytic bronchiolitis (LB) 
    Severe LB (≥B2) 
40(32%) 
21(17%) 
 103(28%) 
           50(13%) 
0.38 
0.17 
 Chronic rejection 60(48%)  126(34%)     0.003* 
 Time to chronic rejection (days)    1097(105)           1183(54) 0.17 
 Death  48(38%)  121(32%) 0.24 
Time to death (days)    1161(168)            825(84) 0.13 
Respiratory infections 50(40%)           126(34%) 0.19 
GERD 49(40%)  143(38%) 0.66 
CMV infection               7(6%)            30(8%) 0.41 
CMV status 
                D+/R+ 
                D+/R- 
                D-/R+ 
                D-/R- 
                Unknown 
 
23(18%) 
20(16%) 
28(23%) 
38(30%) 
15(13%) 
 
64(17%) 
77(21%) 
80(21%) 
  102(28%) 
50(13%) 
0.81 
0.72 
0.27 
0.79 
0.45 
0.71 
Time Ischemia(min) 312(99)            319(101) 0.42 
PGD 
               Grade I 
               Grade II 
               Grade III 
               Unknown 
 
51(41%) 
30(24%) 
13(10%) 
30(25%) 
 
           151(40%) 
           89(24%) 
           46(12%) 
           87(24%) 
0.61 
0.90 
0.92 
0.43 
0.84 
  
Table 1: Characteristics of the cohort, subdivided according to rs879574 genotypes. 
Analysis is preformed with a t-test or a chi-square. Results are shown in numbers (percentage) or with 
the MEAN±SEM. A p-value < 0.05 was considered significant. LTx=lung transplantation; SS= double 
sided LTx, S=single sided LTx; HL=heart-lung transplantation; α-1ATD=alpha-1-antitrypsin 
deficiency; CF= cystic fibrosis; PAHT= pulmonary arterial hypertension; AZI=azithromycin, 
AR=acute rejection, LB= lymphocytic bronchiolitis, GERD= Gastroesophageal reflux disease, CMV= 
cytomegalovirus, PGD= primary graft dysfunction. 
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IL-17R polymorphism HR 95% CI P-value 
Mortality 1.00  [0.708-1.411]             0.14 
Chronic rejection 1.47 [1.069-2.028]            0.004 
BAL Estimate 95% CI P-value 
% Neutrophils 1.59 [1.066-2.356]            0.023 
Total neutrophils 
% Lymphocytes 
                        1.68 
                      0.90 
[1.088-2.608] 
[0.683-1.193] 
           0.020 
           0.471 
Total lymphocytes 1.30 [0.967-1.740]            0.082 
Total WBC 1.34 [1.082-1.645]            0.007 
IL-8/CxCL8 1.13 [0.783-1.624]            0.518 
Blood Estimate 95% CI P-value 
CRP 1.31 [0.976-1.750]            0.072 
 
Table 2: Multivariate-analysis of chronic rejection and mortality for the rs879574 genotypes (AA/AT versus TT) (upper part). Using a proportional 
hazards Cox model with corrections for age, gender, LTx type, diagnosis, time of transplantation and the use of azithromycin. Hazard ratio (HR) and 95% 
confidence interval are used. Estimates of lung and systemic inflammation in association with Il-17R polymorphisms (lower part). We applied Cox 
regression to estimate the hazard ratio of chronic rejection and mortality associated with the genotypes for the selected genetic variants, while 
adjusting for age, gender, time of LTx, type of LTx, underlying lung disease and use of azithromycin. A p-value < 0.05 was considered significant. 
WBC= white blood cells, HR= hazard ratio, CRP= C-reactive protein.  
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Figure 2 
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